BrainsWay Says Cigna Evernorth Ends Prior Authorization for TMS Coverage Starting March 6, 2026

Reuters02-18
BrainsWay Says Cigna Evernorth Ends Prior Authorization for TMS Coverage Starting March 6, 2026

BrainsWay Ltd. said Evernorth Behavioral Health, a division of the Cigna Group serving more than 18 million covered lives across 12 states, will eliminate prior authorization requirements for transcranial magnetic stimulation (TMS) for contracted providers treating patients covered under Evernorth and Cigna Healthcare plans. BrainsWay said Evernorth’s change is effective March 6, 2026. The company added that Evernorth currently covers TMS for major depressive disorder in adolescents and adults and for obsessive-compulsive disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainsway Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602180730PRIMZONEFULLFEED9655655) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment